fexofenadine and alfentanil

fexofenadine has been researched along with alfentanil in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A	1
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D	1

Reviews

1 review(s) available for fexofenadine and alfentanil

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for fexofenadine and alfentanil

Article	Year
Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Journal of clinical pharmacology, 2005, Volume: 45, Issue:1 Topics: Adult; Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Male; Terfenadine	2005
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:4 Topics: Adult; Alfentanil; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Intestines; Liver; Male; Methadone; Narcotics; Pupil; Ritonavir; Stereoisomerism; Terfenadine	2008

Article

Year

Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.

Journal of clinical pharmacology, 2005, Volume: 45, Issue:1

Topics: Adult; Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Male; Terfenadine

2005

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:4

Topics: Adult; Alfentanil; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Humans; Intestines; Liver; Male; Methadone; Narcotics; Pupil; Ritonavir; Stereoisomerism; Terfenadine

2008

Other Studies

2 other study(ies) available for fexofenadine and alfentanil

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
QSAR-based permeability model for drug-like compounds. Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8 Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2011

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

QSAR-based permeability model for drug-like compounds.

Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8

Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2011